课题基金 / 基金详情

项目摘要

项目成果

PAUL J LIMBURG的其他基金

相似基金

相关文献

中文摘要
翻译
美国国家癌症研究所(NCI)癌症预防部门(DCP)0/I/II期癌症预防临床试验计划支持早期临床试验,以快速评估DCP感兴趣的癌症预防药物的临床活性和生物效果。拟研究的药剂应包括制药行业开发并提供给DCP用于协作开发的药剂、商业上可用的药剂和DCP开发的药剂。本任务单的目标是提供核心基础设施,以支持临床试验的进行。
英文摘要
The National Cancer Institute (NCI), Division of Cancer Prevention (DCP) Phase 0/I/II Cancer Prevention Clinical Trials Program supports early clinical trials to rapidly evaluate the clinical activity and biologic effects of cancer preventive agents of interest to DCP. The agents to be studied shall include agents developed by the pharmaceutical industry and provided to DCP for collaborative development, commercially available agents, and agents developed by DCP. The objectives of this Task Order are to provide the core infrastructure to support the conduct of the clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IGF::OT::IGF IGF CORE INFRASTRUCTURE SUPPORT
  • 批准号:
    9162606
  • 项目类别:
  • 资助金额:
    $79.77万
  • 财政年份:
    2015
  • 负责人:
    PAUL J LIMBURG
  • 依托单位:
IGF::OT::IGF IGF CORE INFRASTRUCTURE SUPPORT
  • 批准号:
    9217520
  • 项目类别:
  • 资助金额:
    $84.29万
  • 财政年份:
    2015
  • 负责人:
    PAUL J LIMBURG
  • 依托单位:
海外基金